BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that a recommended dose for weekly administration of PEG-SN38 has been established for Phase II studies. The Company will move forward expeditiously to initiate Phase II trials. The Company also announced that it has been granted patent composition of matter protection for its PEG-SN38 compound until 2027.
